Breaking News Instant updates and real-time market news.

GEMP

Gemphire Therapeutics

$9.65

0.54 (5.93%)

, ORIG

Ocean Rig UDW

$0.16

-0.0083 (-4.90%)

17:43
09/19/17
09/19
17:43
09/19/17
17:43

On The Fly: After Hours Movers

HIGHER: Gemphire Therapeutics (GEMP), up 10.1% after announcing plans to advance Gemcabene into Phase 3 clinical development. LOWER: Ocean Rig UDW (ORIG), down 6.95% after announcing it will effect a 1-for-9,200 reverse stock split of its common shares... Iovance Biotherapeutics (IOVA), down 5.2% after filing to sell $50M of common stock. LOWER AFTER EARNINGS: Bed Bath & Beyond (BBBY), down 11.7% after reporting Q2 earnings and giving FY17 guidance that fell short of analyst expectations... FedEx (FDX), down 2% after reporting disappointing Q1 earnings due to a June 27 cyberattack and the impact of Hurricane Harvey, and giving FY18 guidance that was below the analyst consensus... Adobe (ADBE), down 3.2% after reporting Q3 earnings and giving Q4 guidance.

GEMP

Gemphire Therapeutics

$9.65

0.54 (5.93%)

ORIG

Ocean Rig UDW

$0.16

-0.0083 (-4.90%)

IOVA

Iovance Biotherapeutics

$8.55

0.3 (3.64%)

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

FDX

FedEx

$216.00

0.92 (0.43%)

ADBE

Adobe

$156.60

0.83 (0.53%)

  • 19

    Sep

  • 19

    Sep

  • 19

    Sep

  • 19

    Sep

  • 21

    Sep

  • 25

    Sep

  • 25

    Sep

  • 22

    Oct

GEMP Gemphire Therapeutics
$9.65

0.54 (5.93%)

08/08/17
JEFF
08/08/17
NO CHANGE
Target $18
JEFF
Buy
Gemphire Therapeutics price target lowered to $18 from $32 at Jefferies
Jefferies analyst Matthew Andrews lowered his price target for Gemphire Therapeutics to $18 after reducing his probability of success estimate in heterozygous familial hypercholesterolemia and primary hypercholesterolemia with atherosclerotic cardiovascular disease to 50% from 70%. While gemcabene's absolute reduction of 17.2% is encouraging, the 11.7% placebo-adjusted is below expectations and "somewhat disappointing," Andrews tells investors in a research note. He keeps a Buy rating on Gemphire Therapeutics.
08/08/17
ADAM
08/08/17
NO CHANGE
Target $31
ADAM
Buy
Gemphire Therapeutics weakness overdone, says Canaccord
Canaccord analyst John Newman said Gemphire Therapeutics reported positive top line results for its Phase 2b ROYAL-1 trial, but they were slightly below expectations. He said the safety profile of gemcabene was clean, which is very important going forward. Newman said the recent weakness in the shares is overdone and he reiterated his Buy rating and $31 price target on Gemphire shares.
08/01/17
JEFF
08/01/17
NO CHANGE
Target $32
JEFF
Buy
Gemphire Therapeutics price target raised to $32 from $17 at Jefferies
Jefferies analyst Matthew Andrews raised his price target for Gemphire Therapeutics to $32 after hosting the company for a roadshow. Ahead of the ROYAL-1 data in Q3, the analyst has continued confidence that gemcabene can achieve 20%-plus LCL-C lowering in heterozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease. He notes Gemphire's equity value is a large discount to other metabolic pure play biotechs, which he views as unjustified. The analyst keeps a Buy rating on the shares.
08/31/17
HCWC
08/31/17
INITIATION
Target $21
HCWC
Buy
Gemphire Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Ed Arce started Gemphire Therapeutics with a Buy rating and $21 price target. The share selloff following the ROYAL-1 results is overdone, Acre tells investors in a research note. The company's "novel approach" for nonalcoholic steatohepatitis, including a validated target, has so far been ignored by the Street, the analyst contends.
ORIG Ocean Rig UDW
$0.16

-0.0083 (-4.90%)

IOVA Iovance Biotherapeutics
$8.55

0.3 (3.64%)

08/31/17
HCWC
08/31/17
NO CHANGE
Target $16
HCWC
Buy
Iovance 'fired another shot across the bow of CAR-Ts,' says H.C. Wainwright
The approval of Novartis' (NVS) Kymriah is a "major leap forward" for oncology and immunotherapy, but there remains "significant room for differentiated products," H.C. Wainwright analyst Joseph Pantginis tells investors in a research note on Iovance Biotherapeutics (IOVA) titled "Pins Set Up: Kite Acquired and Kymriah Approved; TILs Can Knock 'Em Down; Reiterate Buy." The analyst believes Iovance's TILs, or tumor infiltrating lymphocytes, could be significantly differentiated from CAR-Ts like Kymriah. He says the TIL platform has a "significantly" more benign safety profile relative to CAR-Ts and growing evidence that it could effectively target solid tumors, an area where he thinks CAR-Ts continue to struggle. Pantginis thinks Iovance "fired another shot across the bow of CAR-Ts" with last night's ESMO conference abstracts. The company released preliminary data that it can generate highly active TILs from lymphoma tumors, the analyst contends. He reiterates a Buy rating on Iovance with a $16 price target. The shares closed yesterday down 30c to $5.55.
09/01/17
WELS
09/01/17
NO CHANGE
WELS
Outperform
Iovance fast track designation 'particularly validating,' says Wells Fargo
Wells Fargo analyst Jim Birchenough views Iovance Biotherapeutics' fast track designation from the FDA for its tumor infiltrating lymphocyte product LN-144 as "particularly validating for a novel cell therapy." The designation establishes unmet need for patients and could support a "more reasonable" Phase 3 hurdle, Birchenough tells investors in a research note. He has an Outperform rating on Iovance.
09/13/17
HCWC
09/13/17
NO CHANGE
Target $16
HCWC
Buy
Iovance expanding on multiple fronts, says H.C. Wainwright
Iovance Biotherapeutics released data at ESMO that it can generate highly active tumor infiltrating lymphocytes from lymphoma tumors, H.C. Wainwright analyst Joseph Pantginis tells investors in a research note titled "Targeting Liquid Tumors and Automating the Supply Chain; Iovance Expanding on Multiple Fronts." The analyst says that while clinical efficacy of these expanded TILs remains unknown, he sees "significant safety profile differentiation" when compared to CAR-Ts. He notes that Iovance is also building new partnerships to make the supply chain run more efficiently. Pantginis keeps a Buy rating on the shares with a $16 price target.
08/03/17
OPCO
08/03/17
INITIATION
Target $13
OPCO
Outperform
Iovance Biotherapeutics initiated with an Outperform at Oppenheimer
Oppenheimer analyst Mark Breidenbach initiated Iovance Biotherapeutics with an Outperform and a $13 price target saying its tumor infiltrating lymphocytes therapy has been clinically validated by several academic institutions and expects to see a stream of clinical readouts from three ongoing company-sponsored trials in the next 12-18 month. Breidenbach expects lovance's path to commercialization in solid tumors to be simplified due to to the trailblazing of personalized CAR-T therapies for blood cancers.
BBBY Bed Bath & Beyond
$27.03

-0.27 (-0.99%)

09/14/17
UBSW
09/14/17
NO CHANGE
Target $30
UBSW
Neutral
Bed Bath & Beyond likely to reduce guidance, says UBS
UBS analyst Michael Lasser does not think Q2 will mark a significant turnaround in Bed, Bath & Beyond's fortunes. He believes competition will lead to further deterioration in same-store sales, leaving them in negative territory for Q2. He also does not believe its profitability will stabilize, something investors will look for before rewarding it with a meaningfully higher multiple. Lasser maintained his Neutral rating and lowered his price target to $30 from $33 on Bed, Bath & Beyond shares.
06/23/17
JEFF
06/23/17
NO CHANGE
Target $34
JEFF
Hold
Bed Bath & Beyond price target lowered to $34 from $41 at Jefferies
Jefferies analyst Daniel Binder said that Bed Bath & Beyond's worse than expected Q1 results, along with its increased investments, could put its guidance at risk. He lowered his price target on the Bed Bath shares to $34 from $41 and keeps a Hold rating on the stock.
07/26/17
LOOP
07/26/17
NO CHANGE
LOOP
Loop lists Bed Bath & Beyond, Dollar Tree as most likely to attract activist
Loop Capital analyst Anthony Chukumba said his analysis leaves him believing Bed Bath & Beyond (BBBY) and Dollar Tree (DLTR) are currently the most likely activist targets among the specialty hardlines retailers he covers. The analyst has a Hold rating on Bed Bath and Buy rating on Dollar Tree.
09/19/17
LOOP
09/19/17
NO CHANGE
LOOP
Bed Bath & Beyond Q2 results 'much worse than expected,' says Loop Capital
Loop Capital analyst Anthony Chukumba said in a research note that at first glance, Bed Bath & Beyond's Q2 results and guidance were "much worse than we expected," and the miss implied "the ongoing deterioration in the company's fundamentals has accelerated." Chukumba was particularly worried by the combination of a comparable sales drop and a year-over-year gross margin decline, and kept a Hold rating and $35 price target on Bed Bath & Beyond shares.
FDX FedEx
$216.00

0.92 (0.43%)

09/15/17
UBSW
09/15/17
DOWNGRADE
UBSW
Neutral
FedEx downgraded to Neutral from Buy at UBS
UBS analyst Thomas Wadewitz downgraded FedEx to Neutral with a $233 price target to reflect TNT issues following the cyber-attack in June that knocked out multiple systems. Wadewitz said it is remains unclear if international operation, delivery confirmation and billing systems are fully running and thinks the resulting impact on volumes could last, reducing FedEx's ability to deliver 10%-15% earnings growth in 2018/19. The analyst believes FedEx risk/reward is balanced in the near-term and sees less clarity in FY18 with risk from TNT.
09/14/17
SBSH
09/14/17
NO CHANGE
SBSH
Buy
Citi sees 'tricky' setup into FedEx's Q1 results
Citi analyst Christian Wetherbee thinks the setup is "tricky" into FedEx's Q1 results next week. The stock has rallied off the post-cyber-attack lows into what should be a "messy" quarter, Wetherbee tells investors in a pre-earnings research note. He estimates the earnings per share impact of the TNT cyber-attack to be in the 50c-$1.00 range for FY18. As a result, Wetherbee expects FedEx to cut its full-year guidance. He recommends buying the shares on any post-earnings weakness, however. The company's long-term story "remains quite attractive," Wetherbee writes. He keeps a Buy rating on FedEx with a $235 price target and continues to see long-term value of $260-$290 per share.
09/15/17
09/15/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Equifax (EFX) downgraded to Hold from Buy at Argus with analyst Jasper Hellweg citing news of a major hack on the company's data that could have lasting effects. 2. FedEx (FDX) downgraded to Neutral from Buy at UBS with analyst Thomas Wadewitz citing TNT issues following the cyber-attack in June that knocked out multiple systems. 3. Carnival (CCL) downgraded to Neutral from Outperform at Credit Suisse with analyst Tim Ramskil saying he is worried that his estimate of absolute industry capacity growth in 2018-2021 is double that of the last five years. 4. American Airlines (AAL), United Continental (UAL), and Spirit Airlines (SAVE) were downgraded to Neutral from Overweight at JPMorgan. 5. Acuity Brands (AYI) downgraded to Market Perform from Outperform at Wells Fargo with analyst Richard Kwas saying his firm's electrical channel checks indicate the 8% consensus organic revenue growth estimate for FY18 does not have upside. The analyst thinks shares are likely range-bound in the $160-$200 range "for the time being." He believes a "material step up" in tiered solutions growth is needed for gross margin to outperform expectations. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/15/17
FBCO
09/15/17
NO CHANGE
Target $242
FBCO
Outperform
FedEx 2020 operating income target may still be achievable, says Credit Suisse
Credit Suisse analyst Allison Landry acknowledges that the damage to FedEx from the cyber attack on TNT is likely significant and she is not recommending that investors buy into FedEx's Q1 report next week. However, to the extent that the company can convince that the TNT situation is contained and that it can still achieve its targeted operating income improvement of $1.2B-$1.5B by 2020, she thinks the report could remove an overhang and be a positive catalyst for the stock. The analyst, who thinks a path to the 2020 target may still be achievable, keeps an Outperform rating on FedEx and raised her price target on the shares to $242 from $237.
ADBE Adobe
$156.60

0.83 (0.53%)

09/06/17
MOFT
09/06/17
INITIATION
Target $195
MOFT
Buy
Adobe initiated with a Buy at MoffettNathanson
MoffettNathanson analyst Adam Holt started Adobe with a Buy rating and $195 price target, as he believes the company's unit growth, selling prices and margin upside can allow it to sustain close to 20% revenue growth for longer than the market currently expects.
08/25/17
08/25/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Walgreens Boots Alliance (WBA) initiated with a Buy and CVS Health (CVS) and Fred's (FRED) initiated with a Hold at Loop Capital. 2. Adobe (ADBE), Intuit (INTU), GoDaddy (GDDY) initiated with a Buy at Jefferies, while Mindbody (MB) was initiated with a Hold. 3. New Oriental Education (EDU), Bright Scholar (BEDU) and TAL Education (TAL) initiated with Overweight ratings at Morgan Stanley. 4. WellCare (WCG) coverage assumed with an Overweight at Cantor. 5. Dollar Tree (DLTR) and Dollar General (DG) reinstated with Buy ratings at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/24/17
JEFF
08/24/17
INITIATION
JEFF
Buy
Adobe initiated with a Buy at Jefferies
Jefferies analyst Brent Thill initiated Adobe with a Buy and a $175 price target.
08/23/17
ADAM
08/23/17
NO CHANGE
Target $110
ADAM
Buy
Buy Salesforce shares if post-earnings weakness persists, says Canaccord
Canaccord analyst Richard Davis called Salesforce's (CRM) Q2 results exceptional and its Q3 deferred guidance conservative. He noted the shares traded lower after the report and said if they stay down, investors should buy the dip. He called Salesforce one of his favorite three large cap growth stocks this year, along with Adobe (ADBE) and ServiceNow (NOW), citing their current valuation and outlook. Davis reiterated his Buy rating and raised his price target to $110 from $100 on Salesforce shares.

TODAY'S FREE FLY STORIES

SYNT

Syntel

$24.30

5.2 (27.23%)

20:37
10/17/17
10/17
20:37
10/17/17
20:37
Upgrade
Syntel rating change  »

Syntel upgraded to Market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

  • 18

    Oct

  • 19

    Oct

  • 14

    Dec

QD

Qudian

20:35
10/17/17
10/17
20:35
10/17/17
20:35
Syndicate
Qudian 37.5M share IPO priced at $24.00 »

The deal priced above the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

ABT

Abbott

$55.06

0.43 (0.79%)

, USB

U.S. Bancorp

$53.88

-0.38 (-0.70%)

20:25
10/17/17
10/17
20:25
10/17/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

ABT

Abbott

$55.06

0.43 (0.79%)

USB

U.S. Bancorp

$53.88

-0.38 (-0.70%)

SVU

Supervalu

$19.38

0.57 (3.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 17

    Jan

UNH

UnitedHealth

$203.89

10.69 (5.53%)

19:58
10/17/17
10/17
19:58
10/17/17
19:58
Recommendations
UnitedHealth analyst commentary  »

UnitedHealth price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

19:25
10/17/17
10/17
19:25
10/17/17
19:25
Conference/Events
The Heritage Foundation hosts President Trump »

President Trump speaks at…

SINA

Sina

$114.26

-0.73 (-0.63%)

19:18
10/17/17
10/17
19:18
10/17/17
19:18
Hot Stocks
Aristeia: Sina claims 'inaccurate' and 'misleading' »

Aristeia Capital, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

CLDR

Cloudera

$15.51

0.13 (0.85%)

, HTHIY

Hitachi

$75.56

-0.49 (-0.64%)

18:57
10/17/17
10/17
18:57
10/17/17
18:57
Hot Stocks
Cloudera, Hitachi form strategic partnership »

Cloudera (CLDR) announced…

CLDR

Cloudera

$15.51

0.13 (0.85%)

HTHIY

Hitachi

$75.56

-0.49 (-0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNFP

Pinnacle Financial

$65.15

-1.15 (-1.73%)

18:35
10/17/17
10/17
18:35
10/17/17
18:35
Earnings
Pinnacle Financial reports Q3 adjusted EPS 90c, consensus 74c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 15

    Nov

FULT

Fulton Financial

$18.95

-0.3 (-1.56%)

18:07
10/17/17
10/17
18:07
10/17/17
18:07
Hot Stocks
Fulton Financial sees FY17 loans & deposits growth mid to high single digits »

Sees FY17 non-interest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 01

    Nov

  • 02

    Nov

EXXI

Energy XXI

$8.59

-0.41 (-4.56%)

18:07
10/17/17
10/17
18:07
10/17/17
18:07
Hot Stocks
Energy XXI provides operational update on Hurricane Nate impact »

Energy XXI provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FULT

Fulton Financial

$18.95

-0.3 (-1.56%)

18:07
10/17/17
10/17
18:07
10/17/17
18:07
Hot Stocks
Fulton Financial cuts Q4 net interest margin view to up 2-6 bp from 3-9 »

Cuts Q4 non-interest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 01

    Nov

  • 02

    Nov

HGV

Hilton Grand Vacations

$39.83

0.05 (0.13%)

17:45
10/17/17
10/17
17:45
10/17/17
17:45
Hot Stocks
Hilton Grand Vacations acquires Sunrise Lodge, terms not disclosed »

Hilton Grand Vacations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

PRGX

PRGX Global

$6.80

0.05 (0.74%)

, KR

Kroger

$20.48

0.04 (0.20%)

17:42
10/17/17
10/17
17:42
10/17/17
17:42
Hot Stocks
PRGX Global signs multi-year technology services contract with Kroger »

PRGX Global (PRGX) signed…

PRGX

PRGX Global

$6.80

0.05 (0.74%)

KR

Kroger

$20.48

0.04 (0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

  • 14

    Dec

UBFO

United Security Bank

$9.50

-0.05 (-0.52%)

17:38
10/17/17
10/17
17:38
10/17/17
17:38
Earnings
United Security Bank reports Q3 EPS 16c versus 12c in year-ago period »

Reports Q3 NII $8.2M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBSH

Union Bankshares

$35.32

-0.18 (-0.51%)

, XBKS

Xenith Bankshares

$32.77

-0.07 (-0.21%)

17:35
10/17/17
10/17
17:35
10/17/17
17:35
Hot Stocks
Xenith Bankshares merger into Union Bankshares receives regulatory approval »

Union Bankshares (UBSH)…

UBSH

Union Bankshares

$35.32

-0.18 (-0.51%)

XBKS

Xenith Bankshares

$32.77

-0.07 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 15

    Nov

OMAB

OMA Airports

$41.34

0.28 (0.68%)

17:35
10/17/17
10/17
17:35
10/17/17
17:35
Hot Stocks
OMA Airports reports Q3 terminal passenger traffic up 1.3% »

Aeronautical revenues per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBM

IBM

$146.54

-0.29 (-0.20%)

17:34
10/17/17
10/17
17:34
10/17/17
17:34
Earnings
IBM sees $2.8B-$2.9B increase in Q4 sales from Q3 »

Sees $300M-$400M boost…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 22

    Oct

  • 15

    Nov

OMAB

OMA Airports

$41.34

0.28 (0.68%)

17:33
10/17/17
10/17
17:33
10/17/17
17:33
Earnings
OMA Airports reports Q3 EPS 66c, consensus 70c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCSS

Select Comfort

$30.38

-0.17 (-0.56%)

17:33
10/17/17
10/17
17:33
10/17/17
17:33
Hot Stocks
Breaking Hot Stocks news story on Select Comfort »

Select Comfort says sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

IBM

IBM

$146.54

-0.29 (-0.20%)

, IBKR

Interactive Brokers

$47.40

-0.32 (-0.67%)

17:32
10/17/17
10/17
17:32
10/17/17
17:32
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: IBM…

IBM

IBM

$146.54

-0.29 (-0.20%)

IBKR

Interactive Brokers

$47.40

-0.32 (-0.67%)

SSKN

STRATA Skin Sciences

$1.75

-0.04 (-2.23%)

HCLP

Hi-Crush Partners

$8.95

0.25 (2.87%)

SCSS

Select Comfort

$30.38

-0.17 (-0.56%)

NAVI

Navient

$12.20

0.47 (4.01%)

CREE

Cree

$29.34

0.06 (0.20%)

AKTX

Akari Therapeutics

$6.40

-0.08 (-1.23%)

MOBL

MobileIron

$3.80

-0.1 (-2.56%)

FOGO

Fogo De Chao

$12.05

0.1 (0.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 18

    Oct

  • 22

    Oct

  • 01

    Nov

  • 15

    Nov

  • 18

    Oct

IBM

IBM

$146.54

-0.29 (-0.20%)

17:32
10/17/17
10/17
17:32
10/17/17
17:32
Hot Stocks
IBM sees increase in gross margin of 2.5 points from Q3 to Q4 »

Says not yet feeling full…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 22

    Oct

  • 15

    Nov

PAYX

Paychex

$62.90

-0.55 (-0.87%)

17:31
10/17/17
10/17
17:31
10/17/17
17:31
Syndicate
Breaking Syndicate news story on Paychex »

Paychex files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

VZ

Verizon

$48.40

0.31 (0.64%)

17:24
10/17/17
10/17
17:24
10/17/17
17:24
Hot Stocks
FCC settles New York City E-rate investigation with Verizon »

The Federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 01

    Nov

SCSS

Select Comfort

$30.38

-0.17 (-0.56%)

17:20
10/17/17
10/17
17:20
10/17/17
17:20
Hot Stocks
Breaking Hot Stocks news story on Select Comfort »

Select Comfort expects to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

IBM

IBM

$146.54

-0.29 (-0.20%)

17:17
10/17/17
10/17
17:17
10/17/17
17:17
Hot Stocks
IBM: Global business services signings up for 3rd consecutive quarter »

Says cognitive solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 22

    Oct

  • 15

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.